Scientists have discovered a powerful gene-targeting system in viruses. Billions of years old, VIPR seems to predate CRISPR and may be even more effective.
Over the past decade, the gene-editing ...
...Now, a new frontier in biotechnology aims to harness this natural mechanism to do something once thought impossible: scrub away the biological detritus of our own past. By mimicking ...
Shares of Scribe Therapeutics, a genetic-medicines company co-founded by Nobel laureate Jennifer Doudna, shot up on their first day of trading Friday, continuing a rebound for biotech IPOs this year.
Scribe sold ...
The inventor of the groundbreaking Crispr gene-editing technology is skeptical about artificial intelligence replacing human effort in the realm of scientific discovery, adding to a growing debate over its ...
For months, the researchers trying to save KJ Muldoon knew him only as ‘Patient Eta’.
He was born in August 2024 with CPS1 deficiency, an ultra‐ rare urea‐cycle disorder that ...
Formation Bio CEO Ben Liu is convinced that drug discovery isn’t the bottleneck in getting medicines to market—it’s going through clinical trials.
Now he’s raised some $615 million from top ...
Long before a lab leak/pangolin connoisseur/over-eager chiropterologist made mRNA vaccines famous, Jake Becraft and Tasuku Kitada were exploring ways in which mRNA technology could be applied to treating disease.
They ...
Researchers at OpenAI and Ginkgo Bioworks showed that an AI model working with an autonomous lab can design and iterate real biology experiments at unprecedented speed.
OpenAI’s GPT can summarize ...
Silicon Valley long salivated at the prospect of disrupting America’s medical system. The country spends some $5trn a year on health care, about a fifth of its GDP and twice as ...
Crispr’s ability to cut genetic code like scissors has just started to turn into medicines. Now, gene editing pioneer Jennifer Doudna wants to build an entire ecosystem to bring ...
TIME's flagship AI newsletter spotlighted Formation Bio CEO Ben Liu and the company's contrarian approach to AI in pharma. While much of the industry has focused on using AI ...
In a deal that Noetik’s leaders call a new paradigm for AI-focused biotech, GSK is paying millions to license AI models rather than drug candidates.
The British pharma giant is ...
Noetik, an AI-native biotech company pioneering self-supervised machine learning and high-throughput spatial data to develop next-generation cancer therapeutics, announced today a five-year strategic collaboration and AI model licensing agreement ...
From decoding the human genome to exploring the universe, science has made huge strides in the 21st century.
While the 21st century has been bumpy, it has also ushered in ...
Biology voices weigh in on the impact of AI on drug discovery from the largest NeurIPS research conference to date.
More than 24,000 machine learning experts gathered for the largest ...
This year, gene-editing technology was customized to fix mutations in a single patient’s genes for the first time.
For a decade after its discovery, CRISPR gene editing was stuck on ...
In 2017, fresh off a PhD on theoretical chemistry, John Jumper heard rumors that Google DeepMind had moved on from building AI that played games with superhuman skill and was starting ...
What if the genome you were born with wasn’t fixed? Eric Kelsic, CEO of Dyno Therapeutics, explains how gene therapy is moving from promise to reality, delivering treatments directly ...
Joe Betts-LaCroix's startup is preparing for its first clinical trial — a pivotal milestone in its war on age-related disease.
For Joe Betts-LaCroix, the answer to every problem seems to ...
Thermal Clients Formation Bio and Georgiamune Named to Fierce Biotech's 2025 Fierce 15
Thermal is proud to announce that clients Formation Bio and Georgiamune have been recognized as two of ...
Jennifer Doudna on CRISPR's Next Frontier: From Rare Disease Breakthroughs to Agricultural Innovation
Nobel Laureate discusses groundbreaking baby KJ case, sickle cell progress, and the future of gene editing at ...
Thermal Clients Featured in WSJ Longevity Investment Deep Dive
Wall Street Journal spotlights the billionaire-backed longevity sector in a comprehensive analysis—featuring two Thermal clients at the center of the boom.
Retro ...
New Center Aims to Scale Personalized CRISPR Cures for Children with Rare Genetic Diseases
Bloomberg covers the launch of the Center for Pediatric CRISPR Cures - a $20M initiative that ...
...Tweaking proteins to do human bidding is nothing new. Enzymes and antibodies, for example, have long endured such outrages. But that is not what Dr Ennist is up to. ...
AI drug discovery and development companies have emerged as one of the hottest areas of the wide-ranging life sciences industry.
Why it matters: As AI-focused biotechs proliferate, VC investors and ...
In 2010, the world of cancer treatment witnessed something remarkable. A new class of drugs called immune checkpoint inhibitors showed unprecedented results in cancers that had long defied treatment. By unleashing ...
During a visit to Lawrence Berkeley National Laboratory (Berkeley Lab), Secretary of Energy Chris Wright today announced a new contract with Dell Technologies to develop NERSC-10, the next flagship ...
The technique used on a 9½-month-old boy with a rare condition has the potential to help people with thousands of other uncommon genetic diseases.
Something was very wrong with Kyle ...
Demis Hassabis is reshaping what’s possible in science. His work at DeepMind—most notably the development of AlphaFold, which earned him a share of the 2024 Nobel Prize in Chemistry—is ...
In early 2005 Rodolphe Barrangou and Philippe Horvath were staring at some very odd bits of repeating genetic code on a computer screen in France. The sequences came from ...
Retro Biosciences is raising a $1bn round to fund the artificial intelligence-powered biotech’s mission to increase human lifespan by a decade, starting by getting its first drug into trials ...
Roche’s exercise of its option concludes initial collaboration and further validates Dyno’s field-leading gene delivery platform and AI-powered sequence design technologies for therapeutic developers
Dyno to receive ...
Genesis Therapeutics started in now-a16z venture capitalist Vijay Pande’s lab at Stanford, where Genesis co-founder and CEO Evan Feinberg did his Ph.D. A16z led Genesis’ 2023 $200 million series B alongside ...
The genome-editing technology can be supercharged by artificial intelligence—and the results are already being felt.
In 2025, we will see AI and machine learning begin to amplify the impact of Crispr genome ...
Company’s first offering, Ataraxis Breast, clinically validated in landmark study to be 30% more accurate than the current standard of care for breast cancer
$4 million in seed ...
The treatment has the potential to cure diseases, but high costs and a difficult delivery process have held it back.
Roche Holding AG is willing to pay more than $1 billion to solve one ...
New strategic partnership leverages the power of the Dyno platform, enabling Roche to advance next-generation AAV gene therapies across multiple targets
Dyno to receive US$50 million upfront cash ...
The technology’s promise can sound like science fiction—it might help us adapt to a radically different climate, or grow organs for people in need—but experts are also concerned about ...
Four years ago, Jennifer Doudna and Emmanuelle Charpentier shared the Nobel Prize in chemistry for the development of a method for genome editing called CRISPR-Cas9.
In her lecture, Doudna detailed “extraordinary and exciting opportunities” for the technology ...
How do we develop and integrate breakthrough health technology into our lives?
From robot helpers to smart prosthetics to "smart skin" to CRISPR gene editing, our ability to build a ...
